5495 results for "*oma"

in 20.98 milliseconds.

• Plasma cell-free small RNA sequencing of pancreatic cancer and control samples

  This dataset contains plasma-derived cell-free small RNA sequencing data from 78 human samples, comprising 39 pancreatic ductal adenocarcinoma patients and 39 control subjects. Each sample was sequenced as a single-end FASTQ library on both Illumina NovaSeq 6000 and Ultima Genomics UG 100 platforms, yielding 156 submitted sequencing runs. The data were generated from SMARTer smRNA-Seq libraries to support comparative analysis of sequencing performance, mature microRNA detection, and pancreatic cancer-associated cell-free small RNA expression across the two platforms.

  Dataset EGAD50000002771

• VIVO Biobank Neuroblastoma Project Data Accession Committee

  Access to neuroblastoma sample data for VIVO Biobank projects.

  Dac EGAC50000000977

• Frequency and prognostic significance of genetic abnormalities in a subgroup of intermediate risk neuroblastoma patients: A SIOPEN study

  Intermediate risk neuroblastoma includes a rare subgroup of patients over the age of 18 months at diagnosis with unresectable, localised tumours with unfavourable histology without MYCN amplification. This group is treated differently around the world with some patients receiving upfront myeloablative therapy (MAT) in addition to standard treatment with chemotherapy, surgery, radiotherapy and 13 cis retinoic acid, but the overall 5-year patient survival with or without MAT is similar (75%). This study aimed to understand the neuroblastoma biology of this rare patient subgroup.

  Study EGAS50000001908

• TNGS data for SIOPEN intermediate-risk neuroblastoma subgroup study

  Targeted next-generation sequencing data for a SIOPEN intermediate-risk neuroblastoma subgroup (age >18 months, localised, unresectable, non-MYCN-amplified neuroblastoma with unfavourable histology), with a total of 31 cases analysed. All but one sample have been analysed using the same workflow, with the exception being NB32. VCF files for the analyses are included in this dataset.

  Dataset EGAD50000002773

• WES data for SIOPEN intermediate-risk neuroblastoma subgroup study

  Whole exome sequencing (WES) data analysed for the SIOPEN intermediate-risk neuroblastoma subgroup (age >18 months, localised, unresectable, non-MYCN amplified neuroblastoma with unfavourable histology), data for a total of 30 cases available. Four samples were analysed as part of another relapse neuroblastoma study (NB02 to NB05), of which two have germline comparison available. The remaining 26 cases had a different analysis workflow, with all but one having germline comparison available. VCF files from WES analyses are included in this dataset.

  Dataset EGAD50000002774

• Arcagen - Gynecologic cancer (ovarian, peritoneal and/or fallopian-tube)

  Arcagen is an EORTC/SPECTA pan-European project that aims to recruit 1000 rare cancer patients from different tumour domains of EURACAN. This study collected samples from advanced or metastatic rare cancer from patients older than 12, and analysed them using Foundation Medicine next-generation sequencing (NGS) panels (FoundationOne CDx for FFPE samples or FoundationOne Liquid CDx for blood samples). Here we are submitting the dataset that contain NGS files in .BAM format from 94 patients with rare ovarian cancer and primary peritoneal cancer and/or fallopian-tube cancer, including low grade serous carcinoma, mucinous adenocarcinoma, clear cell adenocarcinoma; and other rare cancers such as sex cord tumors, germ cell tumor, yolk sac tumor, and malignant/immature teratoma.

  Dataset EGAD50000001315

• Hit counts dataset from RNAseq and single-cell mutiple myeloma analysis

  Hit counts from 60 samples from multiple myeloma patients. The sample were sequenced by bulk RNAseq and/or single cell RNAseq.

  Dataset EGAD50000002713

• Multiple Myeloma Microenvironement Leukemia Canther DAC

  Dac EGAC00001003566

• Arcagen - Skin cancer

  Arcagen is an EORTC/SPECTA pan-European project that aims to recruit 1000 rare cancer patients from different tumour domains of EURACAN. This study collected samples from advanced or metastatic rare cancer from patients older than 12, and analysed them using Foundation Medicine next-generation sequencing (NGS) panels (FoundationOne CDx for FFPE samples or FoundationOne Liquid CDx for blood samples). Here we are submitting the dataset that contain NGS files in .BAM format from 49 patients diagnosed with adnexal carcinoma of the skin, Merkel cells cancer or malignant melanoma of the uvea.

  Dataset EGAD50000000705

• Arcagen - Head and Neck malignancies

  Arcagen is an EORTC/SPECTA pan-European project that aims to recruit 1000 rare cancer patients from different tumour domains of EURACAN. This study collected samples from advanced or metastatic rare cancer from patients older than 12, and analysed them using Foundation Medicine next-generation sequencing (NGS) panels (FoundationOne CDx for FFPE samples or FoundationOne Liquid CDx for blood samples). Here were are submitting the dataset that contains NGS files in .BAM from 102 patients diagnosed with salivary gland tumors of major salivary gland; salivary gland type tumors of head and neck with a strong focus on acinic cell carcinoma (diagnostic based on morphology, but IHC can be performed for DOG1 and SOX10), NUT carcinoma (presence of NUT, cytokeratin and p40 by IHC) and sinus carcinoma.

  Dataset EGAD50000000885